Kaya C, et al. - In patients with exudative age-related macular degeneration (eAMD) with persisting intraretinal fluid on anti-VEGF monotherapy, researchers conducted this retrospective, interventional case series to compare the impact of adding a corticosteroid or switching to another anti-VEGF treatment. For this investigation, they included 43 pseudophakic eyes with eAMD and persistent intraretinal fluid on anti-VEGF treatment that switched treatment to a combination of Ozurdex® or Triamcinolone and anti-VEGF therapy (group 1) or to another anti-VEGF agent (group 2). The authors discovered that corticosteroids achieved a comparable functional and morphological outcome over 12 months as switching to another anti-VEGF therapy in eyes with eAMD with persistent intraretinal fluid on anti-VEGF monotherapy in spite of frequent re-injections, but with a decreased injection burden. Therefore, in selected cases, corticosteroid treatment in refractory exudative AMD may be an option for third-line therapy.